Nektar Therapeutics (NASDAQ:NKTR) – Equities researchers at Seaport Global Securities issued their Q2 2018 EPS estimates for Nektar Therapeutics in a research report issued on Wednesday, May 16th. Seaport Global Securities analyst C. Davis forecasts that the biopharmaceutical company will earn $5.66 per share for the quarter. Seaport Global Securities has a “Buy” rating and a $120.00 price target on the stock. Seaport Global Securities also issued estimates for Nektar Therapeutics’ Q3 2018 earnings at ($0.60) EPS, Q4 2018 earnings at ($0.67) EPS, FY2018 earnings at $3.12 EPS, FY2019 earnings at ($3.03) EPS, FY2020 earnings at ($3.22) EPS, FY2021 earnings at ($2.53) EPS and FY2022 earnings at ($0.84) EPS.
Other research analysts have also recently issued research reports about the stock. Canaccord Genuity increased their target price on shares of Nektar Therapeutics to $94.00 and gave the stock a “buy” rating in a report on Friday, March 2nd. Jefferies Group increased their target price on shares of Nektar Therapeutics to $103.00 and gave the stock a “buy” rating in a report on Friday, March 2nd. HC Wainwright set a $125.00 target price on shares of Nektar Therapeutics and gave the stock a “buy” rating in a report on Monday. Mizuho reissued a “buy” rating and issued a $89.00 target price on shares of Nektar Therapeutics in a report on Wednesday, February 14th. Finally, Piper Jaffray assumed coverage on shares of Nektar Therapeutics in a report on Friday, April 13th. They issued an “overweight” rating and a $125.00 price objective for the company. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $79.50.
Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). The company had revenue of $38.02 million during the quarter, compared to the consensus estimate of $35.59 million. Nektar Therapeutics had a negative return on equity of 202.41% and a negative net margin of 40.07%. The firm’s revenue was up 53.7% compared to the same quarter last year. During the same period last year, the company posted ($0.42) EPS.
A number of hedge funds and other institutional investors have recently modified their holdings of NKTR. Eagle Asset Management Inc. acquired a new stake in Nektar Therapeutics during the 4th quarter valued at approximately $61,577,000. Northern Trust Corp increased its position in Nektar Therapeutics by 38.5% during the 1st quarter. Northern Trust Corp now owns 2,605,818 shares of the biopharmaceutical company’s stock valued at $276,893,000 after purchasing an additional 723,967 shares during the period. Carillon Tower Advisers Inc. acquired a new stake in Nektar Therapeutics during the 4th quarter valued at approximately $43,024,000. Frontier Capital Management Co. LLC acquired a new stake in Nektar Therapeutics during the 1st quarter valued at approximately $71,838,000. Finally, Franklin Resources Inc. acquired a new stake in Nektar Therapeutics during the 1st quarter valued at approximately $69,643,000. Institutional investors and hedge funds own 90.15% of the company’s stock.
In related news, CFO Gil M. Labrucherie sold 90,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 3rd. The shares were sold at an average price of $84.05, for a total value of $7,564,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Howard W. Robin sold 130,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 3rd. The shares were sold at an average price of $84.05, for a total transaction of $10,926,500.00. Following the completion of the transaction, the chief executive officer now owns 280,481 shares of the company’s stock, valued at approximately $23,574,428.05. The disclosure for this sale can be found here. In the last quarter, insiders sold 797,359 shares of company stock valued at $73,089,550. 6.10% of the stock is owned by company insiders.
Nektar Therapeutics Company Profile
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain based on its PEGylation and polymer conjugate technology platforms in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.